Josh Beckerman

1 week ago | tradingview.com | Josh Beckerman

Less than 1 min readSCLXBy Josh BeckermanScilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis. The company's Gloperba, licensed from Romeg Therapeutics, is a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares. Scilex shares were recently down 7% to $6.43, recovering from a 52-week low of $5.90 earlier Wednesday.

1 week ago | tradingview.com | Josh Beckerman

By Josh BeckermanThe Allegheny County Airport Authority plans sell $421.9 million of airport revenue bonds to finance capital improvements at Pittsburgh International Airport. The authority plans to issue $376.6 million of Series 2025 A bonds, which are subject to the alternative minimum tax. It also plans to offer $45.3 million of Series 2025 B federally taxable bonds, according to documents posted on MuniOS. Pricing is expected April 22 and closing is scheduled for April 30.

2 weeks ago | morningstar.com | Josh Beckerman

By Josh Beckerman Aldeyra Therapeutics shares fell 73% to $1.42 in the regular session after it reported a Food and Drug Administration complete response letter for reproxalap for treatment of dry eye disease. The stock touched a 52-week low of $1.14 Thursday. After hours, shares were up 15% to $1.63. An FDA complete response letter indicates that an application can't be approved in its current form.

2 weeks ago | marketscreener.com | Josh Beckerman

By Josh Beckerman Amgen said the Food and Drug Administration approved Uplizna for Immunoglobulin G4-related disease, the second approved indication. The biotechnology company said Thursday the FDA granted breakthrough therapy designation. In 2020, the FDA approved Uplizna for AQP4-IgG+ Neuromyelitis Optica Spectrum Disorder. Amgen is also working toward approval for generalized myasthenia gravis. Write to Josh Beckerman at [email protected] (END) Dow Jones Newswires 04-03-25 1625ET

3 weeks ago | tradingview.com | Josh Beckerman

Novavax Falls But Then Recovers After Report on Vaccine's FDA StatusNVAXNovavax shares declined right after The Wall Street Journal reported that the Food and Drug Administration is unlikely to give full approval soon for a company Covid-19 vaccine, but then the stock recovered. Shares went as low as $5.70. They recently traded at $6.20, up 3.2%. The vaccine is approved for emergency use.